Erythromycin Tablets, 500 mg recall — Zydus Pharmaceuticals (usa) Inc (Class II)

Zydus Pharmaceuticals (usa) Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Erythromycin Tablets, 500 mg — a Class II recall, initiated 2026-04-29 and posted to the FDA enforcement report on 2026-05-27, under recall number D-0545-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit”. From the product description, the form is tablets, the strength given is 500 mg, the package is described as 30 tablets and it is marked Rx only. 1 National Drug Code number is printed in the record: 70710-1048-3. Distribution is recorded as “Nationwide within the U.S” — Nationwide (US), with the recalling firm on record in NJ, United States. The FDA files it under event ID 98870 together with 1 other recall number, all listed and linked below. Within that event this is the strength 500 mg, package 30 tablets and ndc 70710-1048-3 configuration; the sibling records differ on strength, package and ndc and match on everything else the source states. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0545-2026
FDA event ID 98870 (2 recall numbers)
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Zydus Pharmaceuticals (usa) Inc
Recall initiated 2026-04-29
Reported by FDA 2026-05-27
Report lag 28 days from initiation to report
Distribution Nationwide within the U.S — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Erythromycin Tablets, USP, 500 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; (NDC 70710-1048-3).

Reason reported by FDA

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

11 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 29-word product description above; each is a literal substring of it.

Product named Erythromycin Tablets
Form Tablets
Strength 500 mg
Package 30 tablets
NDC 70710-1048-3
Marketing category Rx only
Manufactured by Zydus Lifesciences Ltd., Ahmedabad
Distributed by Zydus Pharmaceuticals (USA) Inc., Pennington

Which configuration this record is

2 recall numbers share event 98870. They differ on strength, package and ndc and agree on everything else the source states, so those are the values to check a package against.

Attribute This record (D-0545-2026) D-0544-2026
Strength 500 mg 250 mg
Package 30 tablets 30 tablets · 30 count bottles · 100 count bottles
NDC 70710-1048-3 70710-1047-3 · 70710-1047-1

Shared across all 2 records under this event: form Tablets; product named Erythromycin Tablets; fda tier Class II; recalling firm Zydus Pharmaceuticals (usa) Inc; the same reason text; initiated 2026-04-29; reported 2026-05-27.

Event context: 2 recall numbers under event 98870

One enforcement action, 2 recall numbers: the FDA filed 1 further configuration of this action under event 98870. Each keeps its own recall number and dates.

Recall recordRecall numberFDA tierStrength / formNDCReported
Erythromycin Tablets, 250 mgD-0544-2026Class II250 mg · Tablets70710-1047-32026-05-27

Other indexed recalls from Zydus Pharmaceuticals (usa) Inc

3 indexed records name Zydus Pharmaceuticals (usa) Inc as the recalling firm, across 2 FDA events, reported 2026-05-27 to 2026-08-12. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Mirabegron Extended-Release Tablets, 25 mgD-0745-2026Class II25 mg · Extended-Release Tablets2026-08-12

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Atomoxetine Capsules HCL, 10 mgD-0538-2026Safecor Health, LLCClass II2026-05-27
Liraglutide Injection, 18 mg/3 mLD-0541-2026Lupin Pharmaceuticals Inc.Class II2026-05-27
Gas-X, 125 mgD-0542-2026Haleon US Holdings LLCClass II2026-05-27
Estradiol Gel, 0.1%D-0543-2026Ani Pharmaceuticals, Inc.Class II2026-05-27
cimzia (certolizumab pegol)D-0546-2026Ucb Biosciences Inc.Class II2026-05-27
fentaNYL Citrate, 2,2500 mcg/50mLD-0548-2026Integradose Compounding Services LLCClass II2026-05-27
Vitamin B-Complex, 799 mcg/5mLD-0549-2026Safecor Health, LLCClass II2026-05-27
Oasis Tears PF, 10mLD-0525-2026Oasis Medical, Inc.Class II2026-05-20

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 6 nearest to 2026-05-27 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Buprenorphine Hydrochloride, 0.3mg/mLD-0527-2026Endo Usa, Inc.0.3mg/mL · Injection2026-05-20
Ascend Laboratories, 25 mgD-0547-2026Ascend Laboratories, LLC25 mg · Extended-Release Tablets2026-05-20
DELFLEX, 1.5%D-0512-2026Fresenius Medical Care Holdings, Inc.1.5% · Solution2026-05-13
DELFLEX, 2.5%D-0513-2026Fresenius Medical Care Holdings, Inc.2.5% · Solution2026-05-13
Duloxetine Delayed-Release Capsules, 30 mgD-0514-2026Ajanta Pharma Ltd.30 mg · Delayed-Release Capsules2026-05-13
Duloxetine Delayed-Release Capsules, 60 mgD-0515-2026Ajanta Pharma Ltd.60 mg · Delayed-Release Capsules2026-05-13

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. A search on event 98870 returns all 2 of these recall numbers; a search on D-0545-2026 returns only this configuration. Match a package against 70710-1048-3 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Zydus Pharmaceuticals (usa) Inc (3 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0545-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0545-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-27
Ingested
2026-08-22
Record hash
4fb2e4127c716c95

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.